# US 12,109,190 B2 · Urolithins as immune response enhancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,109,190 B2
- Document ID: US12109190B2
- Status: Granted
- Kind: B2
- Application number: 17/822,027
- Filed: 2022-08-24
- Published: 2023-03-30
- Granted: 2024-10-08
- Earliest claimed: 2018-04-30
- Assignees: Amazentis SA
- Applicants: Amazentis SA
- Inventors: Anurag Singh; Davide D'Amico; Penelope Andreux; William Blanco-Bose; Christopher L. Rinsch
- Web page: https://patentgrep.com/patent/US12109190B2

## CPC

- A61K 31/37: Coumarins, e.g. psoralen
- A61K 31/335: having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0011: {Cancer antigens}
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/16: for influenza or rhinoviruses
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/55511: {Organic adjuvants}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 35/00: Antineoplastic agents
- C07D 311/80: Dibenzopyrans; Hydrogenated dibenzopyrans
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.

## Claims

### Claim 1

A method of vaccination comprising:
a) administering to a subject in need of vaccination an effective amount of a compound of formula (I)
and
b) administering to the subject a vaccine;
wherein the subject is a human or an animal;
A, B, C, D, W, X, Y and Z are each independently selected from H and OH;
or a salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein A, C, D and Z are independently selected from H and OH; and B, W, X and Y are all H.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is selected from urolithin A, urolithin B, urolithin C and urolithin D.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is urolithin A.

### Claim 5 (depends on 1)

The method of claim 1, wherein an immune function or immune health of the subject is improved.

### Claim 6 (depends on 5)

The method of claim 5, wherein A, C, D and Z are independently selected from H and OH; and B, W, X and Y are all H.

### Claim 7 (depends on 5)

The method of claim 5, wherein the compound of formula (I) is selected from urolithin A, urolithin B, urolithin C and urolithin D.

### Claim 8 (depends on 5)

The method of claim 5, wherein the compound of formula (I) is urolithin A.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject is an elderly human person or child.

### Claim 10 (depends on 9)

The method of claim 9, wherein A, C, D and Z are independently selected from H and OH; and B, W, X and Y are all H.

### Claim 11 (depends on 9)

The method of claim 9, wherein the compound of formula (I) is selected from urolithin A, urolithin B, urolithin C and urolithin D.

### Claim 12 (depends on 9)

The method of claim 9, wherein the compound of formula (I) is urolithin A.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject is an elderly human aged 60 years or older.

### Claim 14 (depends on 13)

The method of claim 13, wherein A, C, D and Z are independently selected from H and OH; and B, W, X and Y are all H.

### Claim 15 (depends on 13)

The method of claim 13, wherein the compound of formula (I) is selected from urolithin A, urolithin B, urolithin C and urolithin D.

### Claim 16 (depends on 13)

The method of claim 13, wherein the compound of formula (I) is urolithin A.

### Claim 17 (depends on 1)

The method of claim 1, wherein the subject is immunocompromised.

### Claim 18 (depends on 17)

The method of claim 17, wherein A, C, D and Z are independently selected from H and OH; and B, W, X and Y are all H.

### Claim 19 (depends on 17)

The method of claim 17, wherein the compound of formula (I) is selected from urolithin A, urolithin B, urolithin C and urolithin D.

### Claim 20 (depends on 17)

The method of claim 17, wherein the compound of formula (I) is urolithin A.